Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004 is registered in ClinicalTrials.gov with TVAX Biomedical as lead sponsor.

NCT NCT05685004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05685004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Lead sponsor
TVAX Biomedical
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 27, 2023
Completion date
November 30, 2030
Enrollment
120 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme of brain